-transparent.png){kind=logo}
Virtually all patients with hormone-refractory prostate cancer will eventually succumb to their diseases with no demonstrable increase in survival with any second-line therapy, thus making the conventional approach to the treatment of this disease palliative. The Southwest Oncology Group (SWOG) Genitourinary Committee strategy in investigating therapy for hormone-refractory prostate cancer is focused on the application of biologically guided treatments targeting primary patients with limited prior hormonal therapy, taking into account evolving concepts regarding the definitions of "hormone-refractory" disease and response criteria. This report reviews data from selected SWOG studies conducted in the past 10 years, and outlines the rationale and design of current and future studies conducted by the Genitourinary Committee of the SWOG in hormone-refractory prostate cancer.
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
September 2002,
The Prostate,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
April 2003,
Cancer,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
June 2008,
Cancer,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
March 2001,
The Prostate,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
August 1997,
Oncology (Williston Park, N.Y.),
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
January 2009,
Therapeutic advances in medical oncology,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
January 1995,
Investigational new drugs,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
February 1993,
Investigational new drugs,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
January 1986,
NCI monographs : a publication of the National Cancer Institute,
M H Hussain, and
B Blumenstein, and
M Eisenberger, and
E D Crawford
December 2005,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
